Shiraz E-Medical Journal

Published by: Neoscriber Demo Publisher

Mycobacterium Strain and Type of Resistance in Pulmonary Tuberculosis Patients: A Missed Link in Iran’s National Tuberculosis Plan

Behnam Honarvar 1 , * , Mohsen Moghadami 2 , Amir Emami 3 , Abbas Behzad Behbahani 4 , Mohammad Taheri 5 , Amir Roudgari 6 , Golnar Sami Kashkoli 5 , Mohsen Rezaee 7 , Ehsan Farzanfar 6 , Zahra Zaree 5 , Jamalodin Goharnejad 6 , Fatemeh Khavandegaran 7 and Kamran Bagheri Lankarani 1
Authors Information
1 Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Bactriology and Virology Department, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, IR Iran
5 Central Microbiology Laboratory, Shiraz Health Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
6 Shiraz University of Medical Sciences, Shiraz, IR Iran
7 Shiraz Health Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Shiraz E-Medical Journal: July 2015, 16 (7); e59880
  • Published Online: July 22, 2015
  • Article Type: Research Article
  • Received: February 6, 2015
  • Revised: April 12, 2015
  • Accepted: July 11, 2015
  • DOI: 10.17795/semj27748

To Cite: Honarvar B, Moghadami M, Emami A, Behbahani A B, Taheri M, et al. Mycobacterium Strain and Type of Resistance in Pulmonary Tuberculosis Patients: A Missed Link in Iran’s National Tuberculosis Plan, Shiraz E-Med J. 2015 ; 16(7):e59880. doi: 10.17795/semj27748.

Copyright © 2015, Shiraz University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Honarvar B, Odoomi N, Rezaei A, Haghighi HB, Karimi M, Hosseini A, et al. Pulmonary tuberculosis in migratory nomadic populations: the missing link in Iran's National Tuberculosis Programme. Int J Tuberc Lung Dis. 2014; 18(3): 272-6[DOI][PubMed]
  • 2. Global tuberculosis report 2014. 2014;
  • 3. Varahram M, Nasiri MJ, Farnia P, Mozafari M, Velayati AA. A retrospective analysis of isoniazid-monoresistant tuberculosis: among Iranian pulmonary tuberculosis patients. Open Microbiol J. 2013; 8: 1-5[DOI][PubMed]
  • 4. Sotgiu G, Ferrara G, Matteelli A, Richardson MD, Centis R, Ruesch-Gerdes S, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J. 2009; 33(4): 871-81[DOI][PubMed]
  • 5. Rattan A, Kalia A, Ahmad N. Multidrug-resistant mycobactrium tuberculosis: molecular perspectives. Ind J Tub. 1999; 46: 51
  • 6. Sharma N, Sharma V, Singh PR, Jawed B, Babu V, Kandpal J, et al. Tuberculosis and Molecular Diagnosis. 2013;
  • 7. Liang L, Wu Q, Gao L, Hao Y, Liu C, Xie Y, et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax. 2012; 67(7): 632-8[DOI][PubMed]
  • 8. Chadha SS, Sharath BN, Reddy K, Jaju J, Vishnu PH, Rao S, et al. Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, India. PLoS One. 2011; 6(11)[DOI][PubMed]
  • 9. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008; 8: 15[DOI][PubMed]
  • 10. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008; 177(7): 787-92[DOI][PubMed]
  • 11. Gonzalo X, Drobniewski F. Is there a place for beta-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J Antimicrob Chemother. 2013; 68(2): 366-9[DOI][PubMed]
  • 12. Honarvar B, Lankarani KB, Odoomi N, Roudgari A, Moghadami M, Kazerooni PA, et al. Pulmonary and latent tuberculosis screening in opiate drug users: an essential and neglected approach for harm-reduction facilities. J Addict Med. 2013; 7(4): 230-5[DOI][PubMed]
  • 13. Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, Graham SM, et al. Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet. 2010; 375(9732): 2179-91[DOI][PubMed]
  • 14. Fukushima M, Kakinuma K, Hayashi H, Nagai H, Ito K, Kawaguchi R. Detection and identification of Mycobacterium species isolates by DNA microarray. J Clin Microbiol. 2003; 41(6): 2605-15[PubMed]
  • 15. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368(9547): 1575-80[DOI][PubMed]
  • 16. Matteelli A, Carvalho AC, Dooley KE, Kritski A. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010; 5(6): 849-58[DOI][PubMed]
  • 17. Miller N, Cleary T, Kraus G, Young AK, Spruill G, Hnatyszyn HJ. Rapid and specific detection of Mycobacterium tuberculosis from acid-fast bacillus smear-positive respiratory specimens and BacT/ALERT MP culture bottles by using fluorogenic probes and real-time PCR. J Clin Microbiol. 2002; 40(11): 4143-7[PubMed]
  • 18. Patel RM. Study of production of alpha amylase secreted from parent and mutant strain of Bacillus amyloliquefaciens and optimization of culture condition. 2013;
  • 19. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ. 1969; 41(1): 21-43[PubMed]
  • 20. Coros A, DeConno E, Derbyshire KM. IS6110, a Mycobacterium tuberculosis complex-specific insertion sequence, is also present in the genome of Mycobacterium smegmatis, suggestive of lateral gene transfer among mycobacterial species. J Bacteriol. 2008; 190(9): 3408-10[DOI][PubMed]
  • 21. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2007; 45(8): 2635-40[DOI][PubMed]
  • 22. Aragon LM, Navarro F, Heiser V, Garrigo M, Espanol M, Coll P. Rapid detection of specific gene mutations associated with isoniazid or rifampicin resistance in Mycobacterium tuberculosis clinical isolates using non-fluorescent low-density DNA microarrays. J Antimicrob Chemother. 2006; 57(5): 825-31[DOI][PubMed]
  • 23. Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, et al. Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis. 2012; 205 Suppl 2-40[DOI][PubMed]
  • 24. Ellner JJ. The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: Part II: scientific advances that may provide solutions. Clin Transl Sci. 2009; 2(1): 80-4[DOI][PubMed]
  • 25. Heifets L. Mycobacteriology Laboratory. Clin Chest Med. 1997; 18(1): 35-53[DOI]
  • 26. Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011; 38(3): 516-28[DOI][PubMed]
  • 27. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010; 375(9728): 1830-43[DOI][PubMed]
  • 28. Dheda K, Warren RM, Zumla A, Grobusch MP. Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am. 2010; 24(3): 705-25[DOI][PubMed]
  • 29. Streicher EM, Muller B, Chihota V, Mlambo C, Tait M, Pillay M, et al. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infect Genet Evol. 2012; 12(4): 686-94[DOI][PubMed]
  • 30. van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis. 2000; 182(6): 1788-90[DOI][PubMed]
  • 31. Global incidence and prevalence of selected curable sexually transmitted infections-2008. 2008;
  • 32. World Health Organization . Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB) Policy statement. 2008;
  • 33. O'Riordan P, Schwab U, Logan S, Cooke G, Wilkinson RJ, Davidson RN, et al. Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis: case control study. PLoS One. 2008; 3(9)[DOI][PubMed]
  • 34. Idigoras P, Beristain X, Iturzaeta A, Vicente D, Perez-Trallero E. Comparison of the automated nonradiometric Bactec MGIT 960 system with Lowenstein-Jensen, Coletsos, and Middlebrook 7H11 solid media for recovery of mycobacteria. Eur J Clin Microbiol Infect Dis. 2000; 19(5): 350-4[PubMed]
  • 35. Chauhan DS, Sharma VD, Parashar D, Chauhan A, Singh D, Singh HB, et al. Molecular typing of Mycobacterium tuberculosis isolates from different parts of India based on IS6110 element polymorphism using RFLP analysis. Indian J Med Res. 2007; 125(4): 577-81[PubMed]
  • 36. Feizabadi MM, Shahriari M, Safavi M, Gharavi S, Hamid M. Multidrug-resistant strains of Mycobacterium tuberculosis isolated from patients in Tehran belong to a genetically distinct cluster. Scand J Infect Dis. 2003; 35(1): 47-51[PubMed]
  • 37. Farnia P, Masjedi MR, Nasiri B, Mirsaedi M, Sorooch S, Kazeampour M, et al. Instability of IS6110 patterns in multidrug-resistant strains of Mycobacterium tuberculosis. Epidemiol Infect. 2007; 135(2): 346-52[DOI][PubMed]
  • 38. Honarvar B, Movahedan H, Mahmoodi M, Sheikholeslami FM, Farnia P. Mycobacterium aurum keratitis: an unusual etiology of a sight-threatening infection. Braz J Infect Dis. 2012; 16(2): 204-8[PubMed]
  • 39. Merza MA, Farnia P, Tabarsi P, Khazampour M, Masjedi MR, Velayati AA. Anti-tuberculosis drug resistance and associated risk factors in a tertiary level TB center in Iran: a retrospective analysis. J Infect Dev Ctries. 2011; 5(7): 511-9[PubMed]
  • 40. Mirsaeidi MS, Tabarsi P, Farnia P, Ebrahimi G, Morris MW, Masjedi MR, et al. Trends of drug resistant Mycobacterium tuberculosis in a tertiary tuberculosis center in Iran. Saudi Med J. 2007; 28(4): 544-50[PubMed]
  • 41. Asaad AM, Alqahtani JM. Primary anti-tuberculous drugs resistance of pulmonary tuberculosis in Southwestern Saudi Arabia. J Infect Public Health. 2012; 5(4): 281-5[DOI][PubMed]
  • 42. Gler MT, Guilatco RS, Guray CV, Tupasi TE. Screening outcomes from patients with suspected multidrug-resistant tuberculosis: lessons learned in the Philippines. Int J Tuberc Lung Dis. 2012; 16(10): 1326-30[DOI][PubMed]
  • 43. Ben Kahla I, Marzouk M, Henry M, Bedotto M, Cohen-Bacrie S, Ben Selma W, et al. Molecular characterisation of isoniazid- and rifampicin-resistant Mycobacterium tuberculosis in Central Tunisia. Int J Tuberc Lung Dis. 2011; 15(12): 1685-8[DOI][PubMed]
  • 44. Moaddab SR, Farajnia S, Kardan D, Zamanlou S, Alikhani MY. Isoniazid MIC and KatG Gene Mutations among Mycobacterium tuberculosis Isolates in Northwest of Iran. Iran J Basic Med Sci. 2011; 14(6): 540-5[PubMed]
  • 45. Sharaf-Eldin GS, Saeed NS, Hamid ME, Jordaan AM, Van der Spuy GD, Warren RM, et al. Molecular analysis of clinical isolates of Mycobacterium tuberculosis collected from patients with persistent disease in the Khartoum region of Sudan. J Infect. 2002; 44(4): 244-51[DOI][PubMed]
  • 46. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis. 2012; 12: 37[DOI][PubMed]
  • 47. Flora MS, Amin MN, Karim MR, Afroz S, Islam S, Alam A, et al. Risk factors of multi-drug-resistant tuberculosis in Bangladeshi population: a case control study. Bangladesh Med Res Counc Bull. 2013; 39(1): 34-41[PubMed]
  • 48. Liu J, Wang W, Xu J, Gao M, Li C. Smear-Negative Multidrug-Resistant Tuberculosis a Significance Hidden Problem for MDR-TB Control: An Analysis of Real World Data. J Tuberc Res. 2014; 2014
  • 49. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006; 61(2): 158-63[DOI][PubMed]
  • 50. Ohmori M, Shimouchi A, Ito K, Uchimura K, Yoshiyama T, Mitarai S. [The background of drug-resistant tuberculosis patients on the basis of the annual report database for 2007-2009 in Japan]. Kekkaku. 2012; 87(4): 357-65[PubMed]
  • 51. Bojorquez I, Barnes RF, Flood J, Lopez-Gatell H, Garfein RS, Backer CE, et al. Multidrug-resistant tuberculosis among patients in Baja California, Mexico, and Hispanic patients in California. Am J Public Health. 2013; 103(7): 1301-5[DOI][PubMed]
  • 52. Flor de Lima B, Tavares M. Risk factors for extensively drug-resistant tuberculosis: a review. Clin Respir J. 2014; 8(1): 11-23[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments